Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

Next Previous
Search
Trial Profile

A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Cervical cancer
  • Focus Diagnostic use
  • Sponsors Navidea Biopharmaceuticals

Most Recent Events

  • 16 Apr 2018 Status changed from recruiting to discontinued.
  • 21 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2018.
  • 21 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2018.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top